Who are NCX 470 0.1%'s main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ncx-470-0-1.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

NCX 470 0.1% — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

NCX 470 0.1% (NCX 470 0.1%) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitric oxide-donating prostaglandin F analog. Area: Ophthalmology.

phase 3 Nitric oxide-donating prostaglandin F analog Prostaglandin F receptor (FP receptor); nitric oxide pathway Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

NCX 470 0.1% (NCX 470 0.1%) — Nicox Ophthalmics, Inc.. NCX 470 is a nitric oxide-donating prostaglandin F analog that lowers intraocular pressure by increasing uveoscleral outflow and releasing nitric oxide to enhance trabecular outflow.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
NCX 470 0.1% TARGET	NCX 470 0.1%	Nicox Ophthalmics, Inc.	phase 3	Nitric oxide-donating prostaglandin F analog	Prostaglandin F receptor (FP receptor); nitric oxide pathway

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitric oxide-donating prostaglandin F analog class)

Nicox Ophthalmics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NCX 470 0.1% — Competitive Intelligence Brief. https://druglandscape.com/ci/ncx-470-0-1. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing